Neoplastic Process
FDA Approves GSK’s Blenrep for Multiple Myeloma Treatment, Marking a Market Return
Blenrep; GSK; FDA Approval; Multiple Myeloma; Bortezomib; Dexamethasone
Inhibrx to Seek FDA Approval in 2026 After Strong Phase 2 Data for Bone Cancer Drug Ozekibart
Inhibrx; FDA submission; ozekibart; INBRX-109; chondrosarcoma; bone cancer; phase 2 clinical trial; progression-free survival; death receptor 5; biologics license application; rare cancer; liver toxicity
Terns Ditches Obesity Pill After Phase 2 Letdown, Shifts Focus to Cancer Pipeline
Terns Pharmaceuticals; TERN-601; obesity drug; GLP-1 receptor agonist; Phase 2 trial; weight loss; liver enzyme elevation; oncology; TERN-701; chronic myeloid leukemia (CML); metabolic disease
ESMO Spotlight: Flagship ADCs move into early-stage cancer to validate chemo-displacement ambitions
ESMO 2025; antibody-drug conjugates; ADCs; early-stage cancer; chemo-displacement; trastuzumab deruxtecan; ENHERTU; datopotamab deruxtecan; DATROWAY; breast cancer; HER2-positive; triple-negative breast cancer; biomarkers; toxicity management
Takeda and Innovent Forge $1.2B Upfront Oncology Pact for Bispecific and ADC Therapies, Total Deal Valued Up to $11.4B
Takeda; Innovent Biologics; global strategic partnership; bispecific antibody; antibody-drug conjugate (ADC); oncology; IBI363; IBI343; IBI3001; $1.2 billion upfront; $11.4 billion total deal; cancer therapy; co-development; milestone payments
Ipsen to Acquire ImCheck Therapeutics for €350 Million to Expand Immunotherapy Pipeline
Ipsen; ImCheck Therapeutics; acquisition; €350 million; €1 billion deal; immunotherapy; oncology pipeline; butyrophilin superfamily; ICT01; acute myeloid leukemia; monoclonal antibody; BTN3A
Exelixis’ Kinase Blocker Zanzalintinib Sets New Survival Standard in Third-Line Metastatic Colorectal Cancer, Paving Way for FDA Review
Exelixis; zanzalintinib; kinase inhibitor; colorectal cancer; STELLAR-303 trial; Tecentriq; regorafenib; overall survival; third-line therapy; FDA submission
Replimune Resubmits Melanoma Drug for FDA Approval After Initial Rejection
Replimune; RP1; Melanoma Treatment; FDA Approval; Resubmission
Iambic’s AI-Designed HER2 Inhibitor IAM1363 Shows Early Anti-Tumor Activity in Heavily Pretreated Patients
Iambic Therapeutics; AI-designed drug; IAM1363; HER2 inhibitor; cancer; clinical trial; Phase 1/1b; ESMO 2025; brain-penetrant; tyrosine kinase inhibitor
Tecentriq Demonstrates Survival Benefit in ctDNA-Guided Bladder Cancer Treatment at ESMO 2025
Tecentriq; atezolizumab; ctDNA-guided therapy; IMvigor011; bladder cancer; muscle-invasive bladder cancer; adjuvant treatment; overall survival; disease-free survival; ESMO 2025; Signatera; Genentech; Roche